Timeliness of surgery for early-stage lung cancer: Patient factors and predictors

被引:0
|
作者
Zhu, Jeffrey [1 ]
Kantor, Sydney [1 ]
Zhang, Jiafang [1 ]
Yip, Rowena [1 ]
Flores, Raja M. [2 ]
Henschke, Claudia I. [1 ]
Yankelevitz, David F. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Thorac Surg, New York, NY USA
来源
JTCVS OPEN | 2024年 / 19卷
关键词
delays; early-stage lung cancer; lung cancer; surgical delays; time to treatment; time to treatment initiation; TIME;
D O I
10.1016/j.xjon.2024.02.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Time-to-treatment initiation is an important consideration for patients undergoing thoracic surgery for early-stage lung cancer because delays have the potential to adversely affect outcomes. This study seeks to quantify time-to- treatment initiation for patients with clinical stage I lung cancer, explore patient factors and predictors that lead to an increased time-to-treatment initiation, and compare surgeon perception of appropriate time-to-treatment initiation to the results. Methods: Time-to-treatment initiation was determined for patients enrolled in the Mount Sinai Initiative for Early Lung Cancer Research on Treatment study who underwent surgical resection for clinical stage I lung cancer between March 2016 and December 2021. The following dates were determined: (1) date of fi rst suspicious radiologic imaging, (2) date of fi rst biopsy, and (3) date of surgery. A total of 15 thoracic surgeons who participated in the Mount Sinai Initiative for Early Lung Cancer Research on Treatment were assessed on their perception on time-to- treatment initiation. Results: For 638 patients, median time from fi rst suspicious imaging fi ndings to biopsy was 40 days, biopsy to surgery was 37 days, and suspicious imaging to surgery was 84 days. Significant fi cant factors that resulted in longer time-to-treatment initiation in the multivariate analysis were African American or Black race (P P = .005), vascular disease (P P = .01), and median household income less than $75,000 (P P = .04). Although the surgeon's ' s perception was that the average time from biopsy to surgery was 28 days, it was longer for 63.5% % of participants; surgeon perception of maximum time between diagnosis and surgery was 84 days and longer for 28.7% % of participants. Conclusions: Patient factors such as race, income, and comorbidities were found to have differences in time-to-treatment initiation. Delays to surgery exceeded the expectations of thoracic surgeons. (JTCVS Open 2024;19:325-37)
引用
收藏
页码:325 / 337
页数:13
相关论文
共 50 条
  • [41] Limited Resection for Early-Stage Lung Cancer
    Mekhail, Tarek
    Boyer, Joseph
    [J]. CURRENT ONCOLOGY REPORTS, 2010, 12 (05) : 285 - 287
  • [42] Sublobar resection for early-stage lung cancer
    Sakurai, Hiroyuki
    Asamura, Hisao
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (03) : 164 - 172
  • [43] Moving Immunotherapy Into Early-Stage Lung Cancer
    Linehan, Anna
    Forde, Patrick M.
    [J]. CANCER JOURNAL, 2020, 26 (06): : 543 - 547
  • [45] Early-stage lung cancer: Diagnosis and treatment
    Ohira T.
    Suga Y.
    Nagatsuka Y.
    Usuda J.
    Tsuboi M.
    Hirano T.
    Ikeda N.
    Kato H.
    [J]. International Journal of Clinical Oncology, 2006, 11 (1) : 9 - 12
  • [47] Sublobar Resection for Early-Stage Lung Cancer
    Schuchert, Matthew J.
    Abbas, Ghulam
    Pennathur, Arjun
    Nason, Katie S.
    Wilson, David O.
    Luketich, James D.
    Landreneau, Rodney J.
    [J]. SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2010, 22 (01) : 22 - 31
  • [48] Thoracoscopic Segmentectomy for Early-Stage Lung Cancer
    D'Amico, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1659 - S1660
  • [49] The path forward in early-stage lung cancer
    Cuppens, Kristof
    Baas, Paul
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (01) : 11 - 13
  • [50] Factors influencing patient satisfaction after treatments for early-stage non-small cell lung cancer
    Pompili, Cecilia
    Dalmia, Sanjush
    McLennan Battleday, Finn
    Rogers, Zoe
    Absolom, Kate
    Bekker, Hilary
    Franks, Kevin
    Brunelli, Alex
    Velikova, Galina
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (09) : 2447 - 2454